AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Currently Amended) <u>A biphenyl compound Biphenyl compounds</u> substituted with an aromatic or heteroaromatic radical, characterized in that they correspond to the general formula (I) below:

$$\begin{array}{c|c} & & & \\ \hline & & \\ \hline & & & \\ \hline & & \\$$

in which:

Ar represents an aromatic or heteroaromatic radical chosen from:

Z being O or S,

 R_1 represents -CH₃, -CH₂-OH, -OR₈ or -COR₉,

 R_2 and R_3 , which may be identical or different, represent H, linear or branched C_1 - C_{15} alkyl, cycloalkyl, $-ZR_{10}$ or a polyether radical, at least one from among R_2 and R_3 representing a linear or branched C_4 - C_{15} -alkyl radical, or

R₂ and R₃, taken together, form a 5- or 6- membered ring, optionally substituted with at least one methyl and/or optionally interrupted by an oxygen or sulphur atom or by an SO or SO₂ radical,

 R_4 represents H, a halogen atom, linear or branched C_1 - C_{20} alkyl, -OR₁₀, -OCOR₁₁ or a polyether radical,

R₅ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl,

-OCOR₁₁, -OR₁₂, mono- or polyhydroxyalkyl, -NO₂,

 $-(CH_2)_n - NHCOCH_3, \ -CH = CH - COR_{13}, \ -(CH_2)_n COR_{13}, \ n \ being \ 0 \ to \ 6, \ -O - (CH_2)_m COR_{13}, \ -(CH_2)_n COR_{13}, \ -(CH_2)_n$

-O-(CH₂)_mOH, m being 1 to 12, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, a polyether radical or a -CH₂- polyether radical,

R₆ represents H, lower alkyl or -OR₁₀,

 R_7 represents H, a halogen atom, linear or branched C_1 - C_{20} alkyl, -OR₁₀ or -OCOR₁₁ or a polyether radical,

R₈ represents H, lower alkyl, -COR₁₁,

R₁₀ represents H or lower alkyl,

R₁₁ represents lower alkyl,

R₁₂ represents H, linear or branched C₁-C₂₀ alkyl, mono- or polyhydroxyalkyl, or optionally substituted aryl or aralkyl,

R₁₄ represents H, alkyl, linear or-branched C₄-C₂₀ alkyl, alkenyl, mono- or polyhydroxyalkyl, optionally substituted aryl or aralkyl, or a sugar residue,

r' and r", which may be identical or different, represent H, OH, lower alkyl, mono- or polyhydroxyalkyl, optionally substituted aryl, an amino acid residue or a peptide residue, or r' and r", taken together, form a heterocycle,

or a salt and the salts of the compound compounds of formula (I) when R₄ represents a carboxylic acid function, as well as the or an optical or and geometrical isomer isomers of the compound said compounds of formula (I).

- 2. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that they are in the form of a salt of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.
- 3. (Currently Amended) A compound Compounds according to either of Claim 1, characterized in that the lower alkyl radical is chosen from the group consisting of the methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl radicals.
- 4. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the linear or branched alkyl radical, when it is C_1 - C_{15} , is chosen from the group consisting of the methyl, ethyl, propyl, 2-ethylhexyl, octyl and dodecyl radicals, and, when it is C_1 - C_{20} , is also chosen from the hexadecyl and octadecyl radicals.
- 5. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the monohydroxyalkyl radical is chosen from the group consisting of the hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl and 3-hydroxypropyl radicals.

- 6. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the polyhydroxyalkyl radical is chosen from the group consisting of the 2,3-dihydroxypropyl, 2,3, 4-trihydroxybutyl and 2,3,4,5-tetrahydroxypentyl radicals and the pentaerythritol residue.
- 7. (Currently Amended) A compound Compounds according to Claim 1, characterized in that the polyether radical is chosen from the group consisting of the methoxymethoxy, methoxyethoxy and methoxyethoxymethoxy radicals.
- 8. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the -CH₂-polyether radical is chosen from the group consisting of the methoxymethoxymethyl, ethoxymethoxymethyl and methoxyethoxymethyl radicals.
- 9. (Currently Amended) A compound Compounds according to Claim 1, characterized in that the aryl radical is a phenyl radical optionally substituted with at least one halogen, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.
- 10. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the aralkyl radical is chosen from the group consisting of benzyl and phenethyl radicals optionally substituted with at least one halogen atom, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.
- 11. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the heteroaryl radical is chosen from the group consisting of

pyridyl, furyl and thienyl radicals, optionally substituted with at least one halogen, a lower alkyl, a hydroxyl, a C_1 - C_3 alkoxy, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C_1 - C_6 lower alkyl or alkoxy.

Claims 12-13. (Cancelled)

- 14. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the amino acid residue is chosen from the group consisting of residues derived from lysine, from glycine <u>or-and</u> from aspartic acid.
- 15. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the peptide residue is chosen from the group consisting of dipeptide and tripeptide residues.
- 16. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that when r' and r" form a heterocycle, this is chosen from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C₁-C₆ alkyl or a mono- or polyhydroxyalkyl.
- 17. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that the halogen atom is chosen from the group consisting of fluorine, chlorine and bromine.
- 18. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that they correspond to the general formulae (II) and (III) below:

$$\begin{array}{c} R_{15} \\ R_{17} \\ R_{18} \end{array} \begin{array}{c} R_{16} \\ R_{2} \\ R_{5} \end{array} \begin{array}{c} R_{15} \\ R_{6} \end{array} \begin{array}{c} R_{16} \\ R_{5} \\ R_{6} \end{array} \begin{array}{c} R_{16} \\ R_{10} \\ R_{10} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{2} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{3} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \\ R_{6} \\ R_{6} \\ R_{6} \\ R_{7} \\ R_{10} \\ R_{$$

in which:

Ar represents a radical of formula (a) or (b) below:

$$(a) \qquad (b) \qquad (a)$$

 R_1 , R_4 , R_5 , R_6 , and R_7 [[and Z]] having the same meanings as those given in Claim 1,

 R_{15} , R_{16} , R_{17} and R_{18} , which may be identical or different, represent H or -CH₃, and

t is 1 or 2.

19. (Currently Amended) <u>A compound Compounds</u> according to Claim 1, characterized in that they are taken from the group consisting of:

-4-[4-hydroxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phonyl]bonzoic acid, and its methyl ester,

-4-[4-(5-hydroxypentyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,

-4-[4-(6-hydroxyhexyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phonyl]bonzoic acid, and its methyl ester,

-4-[4-(7-hydroxyheptyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

- 4-[4-8-hydroxyoctyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

-4-[4-(9-hydroxynonyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

- 4-[4-methoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

-4-[4-methoxyethoxymethoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

- 4-[4-benzyloxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,

-4'-(2,3-dihydroxypropoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphonyl-4-carboxylic acid (racemic),

-4'-(2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid (racemic),

-4'-(2-morpholin-4-yl-ethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphonyl-4-carboxylic acid,

- methyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1':4',1"]terphonyl-4"-carboxylate,

-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

-4-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 4-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 4-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-3-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 3-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphonyl-4"-carboxylic acid,

-3-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl-[1,1';4'1"]terphenyl-4"-carboxylic acid,

-2-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphonyl-4-carboxylic acid,

- 2'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';2',1"]terphenyl-4"-carboxylic-acid,
- -2'-methoxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-biphenyl-4'-carboxylic acid,
- 2'-hydroxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- ~2'-methoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 3'-methoxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- -3'-hydroxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
 - -2'-(4,4-dimethylthiochroman-7-yl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,
 - -2'-(4,4-dimethylthiochroman-6-yl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,
- -2'-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2'-(3-methoxymethoxy-5-5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2'-(3-hydroxy-5,5,8,8-totramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphythyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(3-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphonyl-4"-carboxylic acid,

- 3"-methyl-2' (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphanyl-4"-carboxylic acid,

- 2"-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2"-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2"-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2"-propyloxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 3"-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 6-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]nicotinic acid, <u>and</u>

- 5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]2-pyridinecarboxylic acid,
- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-hydroxamic acid,
 - -2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-ol,
- [2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-yl]methanol,
- -2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carbaldehyde,
- 4'-methoxycarbonylmethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 4'-carboxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- -4'-(5-othoxycarbonylpentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 4'-(5-carboxypentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- -2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxamide,
- N-othyl-2'-(5,5,8,8-totramethyl-5,6,7,8-totrahydro-2-naphthyl)[1,1';4',1"]torphonyl-4"-carboxamido,
- N,N-diethyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxamide,

- morpholin-4-yl-[2'-(5,5,8,8-totramothyl-5,6,7,8-totrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-yl]methanone,

- (4-hydroxyphonyl)-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphonyl-4"-carboxamide,

-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxymethyl-4'-carboxylic acid,

-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4,4'-dicarboxylic acid,

-3'-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 3'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

-3'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 3'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';3',1"]terphenyl-4"-carboxylic acid,

-4'-(5-carboxamidopentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 3'-methoxycarbonyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

-3'-carboxyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

-2'-(4-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(4-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2'-(4-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4'1"]terphenyl-4"-carboxylic acid,

-2'-(4-methoxymethoxy-5,5,8,8-teramethyl-5,6,7,8-tetrahydro-2-naphthyl)[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]-4-thiophenecarboxylic acid.

20. (Previously Presented) A compound Compounds according to Claim 1, for use as a medicinal product.

Claims 21-22. (Cancelled)

23. (Currently Amended) <u>A pharmaceutical Pharmaceutical composition</u>, characterized in that it comprises, in a pharmaceutically acceptable support, at least one compound as defined according to Claim 1.

- 24. (Currently Amended) <u>A pharmaceutical composition Composition according</u> to Claim 23, characterized in that the concentration of said at least one compound is between 0.001% and 5% by weight relative to the total weight of the composition.
- 25. (Currently Amended) A cosmetic Cosmetic composition, characterized in that it contains, in a cosmetically acceptable support, at least one compound as defined according to Claim 1.
- 26. (Currently Amended) A cosmetic composition Composition according to Claim 25, characterized in that the concentration of said at least one compound is between 0.001 and 3% by weight relative to the total weight of the composition.

Claim 27. (Cancelled)

- 28. (Previously Presented) A dermatological, immunoallergic, cardiovascular and/or opthalmological treatment method comprising administering a composition comprising a compound according to Claim 1 to a person in need of said treatment.
- 29. (new) A cosmetic treatment method for repairing or combating aging of the skin comprising applying to the part of the skin to be treated a composition comprising a compound according to claim 1 to a person in need of said cosmetic treatment.
- 30. (new) A dermatological, immunoallergic, cardiovascular or ophthalmological treatment method comprising administering a composition comprising a compound according to claim 1, to a person in need of said treatment.

- 31. (new) The method of claim 29, for treating dermatological complaints associated with keratinization disorders.
 - 32. (new) The method of claim 29, for treating acne.
- 33. (new) The method of claim 29, for treating ichthyosis, Darier's diseases, palmoplantar keratoderma, leucophasia and cutaneous or mucous lichen.
- 34. (new) The method of claim 29, for treating psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy.
 - 35. (new) The method of claim 34, for treating eczema.
- 36. (new) The method of claim 29, for treating dermal or epiderman proliferations.
- 37. (new) The method of claim 36, for treating warts, papillomatoses and uvinduced proliferations.
 - 38. (new) The method of claim 30, for treating bullosis or collagen diseases.
 - 39. (new) The method of claim 30, for treating corneopathies.

- 40. (new) The method of claim 30, for treating cutaneous atrophy.
- 41. (new) The method of claim 30, for combating cicatrization disorders or stretch marks.
 - 42. (new) The method of claim 30, for combating seborrhoea.
 - 43. (new) The method of claim 30, for combating arthritis.
 - 44. (new) The method of claim 30, for combating alopecia.
 - 45. (new) The method of claim 30, for combating arteriosclerosis.